Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1 alpha mediated in prostate carcinoma cells

Cancer

Volumn 103, Issue 7, 2005, Pages 1363-1374

  Coffey, Ronan N T ^a,b   Morrissey, Colm ^a,b   Taylor, Cormac T ^a,b   Fitzpatrick, John M ^a,b   Watson, R William G ^a,b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b Dublin Molecular Medicine Centre   (Ireland)

Author keywords

Androgen independence; Apoptosis; Hypoxia; Prostate carcinoma

Indexed keywords

CASPASE; CYTOCHROME C; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROPIDIUM IODIDE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HYPOXIA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

APOPTOSIS; CARRIER PROTEINS; CASPASES; CELL HYPOXIA; CELL NUCLEUS; CYTOCHROMES C; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MITOCHONDRIAL PROTEINS; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 15744366623     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20918     Document Type: Article

References (39)

1. Denmeade SR, Isaacs JT. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol. 1996;35:281-306.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Cancer Rev. 2001;1:34-45.
3. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-381.
4. Shabsigh A, Ghafar MA, de la Taille A, et al. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gains. J Cell Biochem. 2001;81: 437-444.
5. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29:297-307.
6. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxia in human prostate carcinoma: an eppendorf PO2 study. Am J Clin Oncol. 2001;24:458-461.
7. Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998;58:5280-5284.
8. Cvetkovic D, Movsas B, Dicker AP, et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology. 2001;57:821-825.
9. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88: 1474-1480.
10. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxic prostate/muscle PO2 ration predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology. 2002;60:634-639.
11. Movsas B, Chapman JD, Horwitz EM, et al. Hypoxic regions exist in human prostate carcinoma. Urology. 1999; 53:11-18.
12. Park SY, Billiar TR, Seol DW. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun. 2002; 291:150-153.
13. Dong Z, Wang J. Hypoxia selection of death-resistant cells: a role for Bcl-XL. J Biol Chem. 2004;279:9215-9221.
14. Cuisnier O, Serduc R, Laveielle JP, et al. Chronic hypoxia protects against gamma-irradiation-induced apoptosis by inducing bcl-2 up-regulation in inhibiting mitochondrial translocation and conformational change of bax protein. Int J Oncol. 2003;23:1033-1041.
15. Lee VY, McClintock DS, Santore MT, et al. Hypoxia sensitizes cells to nitric oxide-induced apoptosis. J Biol Chem. 2002;277:16067-16074.
16. Brunelle JK, Chandel NS. Oxygen deprivation induced cell death: an update. Apoptosis. 2002;7:475-482.
17. Coffey RNT, Watson RWG, O'Neill AJ, et al. Androgen resistance to apoptosis in the LNCaP cell line; attributable to altered caspase and Bcl-2 expression. Prostate. 2002;53:300-309.
18. Chen M, Wang J. Initiator caspases in apoptosis signalling pathways. Apoptosis. 2002;7:313-319.
19. Pfeil K, Eder IE, Putz T, et al. H. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate. 2004;15:259-268.
20. Dong Z, Wang JZ, Yu F, et al. Apoptosis-resistance of hypoxia cells: multiple factors involved and a role for IAP-2. Am J Pathol. 2003;163:663-671.
21. McEleny KR, Watson RW, Coffey RN, et al. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate. 2002;51:133-140.
22. McEleny K, Coffey R, Morrissey C, et al. An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to Fas and TNFα mediated apoptosis. Prostate. 2004;59: 419-425.
23. Krajewska M, Krajewska S, Banares S, et al. Elevated expression of inhibitors of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003;9:4914-4925.
24. Ghafar MA, Anastasiadis AG, Chen M-W, et al. Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer. Prostate. 2003;54:58-67.
25. Parikh NA, Katsetos CD, Ashraf QM, et al. Hypoxia-induced caspase-3 activation and DNA fragmentation in cortical neurons of newborn piglets: role of nitric oxide. Neurochem Res. 2003;28:1351-1357.
26. Steinbach JP, Wolburg H, Klumpp A, et al. Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ. 2003;10:823-832.
27. Yang QH, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and C-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem. 2004;279:16963-16970.
28. Carson JP, Behnam M, Sutton JN, et al. Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells. Cancer Res. 2002;62:18-23.
29. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
30. Frederiksen LJ, Siemens DR, Heaton JP, et al. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol. 2003;170:1003-1007.
31. Zheng D, Venkatachalam MA, Wang J, et al. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. J Biol Chem. 2001;276:18702-18709.
32. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential pf prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst. 2001;93:208-213.
33. Movsac B, Chapman JD, Horwitz EM, et al. Hypoxia regions exist in human prostate carcinoma. Urology. 1999; 53:11-18.
34. Huss WJ, Hanrahan CF, Barrios RJ, et al. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 2001;61:2736-2743.
35. Salnikow K, Costa M, Figg WD, Blagosklonny MV. Hyperinducibility of hypoxia-response genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res. 2000;60:5630-5634.
36. Dong Z, Nishiyama J, Yi X, Venkatachalam MA, et al. Gene promoter of apoptosis inhibitory protein IAP2: identification of enhancer elements and activation by severe hypoxia. Biochem J. 2002;364:413-421.
37. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998;17:3005-3015.
38. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1 alpha is a positive factor in solid tumour growth. Cancer Res. 2000;60:4010-4015.
39. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nature Rev Cancer. 2002;2:38-47.